Canada · Delayed Price · Currency is CAD Waverley Pharma Statistics
Total Valuation
Waverley Pharma has a market cap or net worth of CAD 540,000. The enterprise value is 3.70 million.
| Market Cap | 540,000 |
| Enterprise Value | 3.70M |
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Waverley Pharma has 54.00 million shares outstanding.
| Current Share Class | 54.00M |
| Shares Outstanding | 54.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 74.90% |
| Owned by Institutions (%) | n/a |
| Float | 13.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.40 |
| PB Ratio | -0.21 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.40 |
| EV / Sales | 2.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.12
| Current Ratio | 0.12 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.97 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -13.27% |
| Return on Invested Capital (ROIC) | -22.88% |
| Return on Capital Employed (ROCE) | 14.61% |
| Weighted Average Cost of Capital (WACC) | 5.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.82 |
| Inventory Turnover | 2.94 |
Taxes
In the past 12 months, Waverley Pharma has paid 1,631 in taxes.
| Income Tax | 1,631 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 1.21 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 41.42 |
| Average Volume (20 Days) | 16,589 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Waverley Pharma had revenue of CAD 1.35 million and -499,214 in losses. Loss per share was -0.01.
| Revenue | 1.35M |
| Gross Profit | 513,677 |
| Operating Income | -349,342 |
| Pretax Income | -497,583 |
| Net Income | -499,214 |
| EBITDA | -266,037 |
| EBIT | -349,342 |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 44,950 in cash and 3.44 million in debt, with a net cash position of -3.40 million or -0.06 per share.
| Cash & Cash Equivalents | 44,950 |
| Total Debt | 3.44M |
| Net Cash | -3.40M |
| Net Cash Per Share | -0.06 |
| Equity (Book Value) | -2.57M |
| Book Value Per Share | -0.05 |
| Working Capital | -3.22M |
Cash Flow
| Operating Cash Flow | -611,033 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 83,305 |
| Net Borrowing | 376,706 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 38.06%, with operating and profit margins of -25.88% and -36.99%.
| Gross Margin | 38.06% |
| Operating Margin | -25.88% |
| Pretax Margin | -36.87% |
| Profit Margin | -36.99% |
| EBITDA Margin | -19.71% |
| EBIT Margin | -25.88% |
| FCF Margin | n/a |
Dividends & Yields
Waverley Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -92.45% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |